Article
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
Thrombosis and haemostasis - 2 Sept 2014
Gurbel P A, Bergmeijer T O, Tantry U S, ten Berg J M, Angiolillo D J, James S, Lindahl T L, Svensson P, Jakubowski J A, Brown P B, Duvvuru S, Sundseth S, Walker J R, Small D, Moser B A, Winters K J, Erlinge D
Abstract excerpt
CYP2C19 genotype has been shown to impact response to clopidogrel 75-mg but not prasugrel 10-mg. Here, we assessed effects of CYP2C19 metaboliser status on pharmacokinetics (PK) and pharmacodynamic (PD) responses to prasugrel 5-mg and 10-mg and clopidogrel 75-mg using data from two PK/PD studies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.